BioInformant

Your Global Leader in Stem Cell Market Research

Home » Interviews » Page 2

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Basilard Biotech to Transform the Engineering of Cell-based Therapies Using Their Novel Nanomechanical Gene Delivery Technology

By Leave a Comment

Basilard Biotech LogoBasilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called SoloPore™. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of current viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more  cost-effective production of cell and gene therapies.

In this interview with Brynley Lee, CEO of Basilard, we learn about the formation of Basilard Biotech, explore the company’s novel SoloPore™ technology, dive into the company’s funding strategy, and explore its future goals. Enjoy! [Read more…]

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

By Leave a Comment

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science! [Read more…]

Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics

By Leave a Comment

Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.

The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.

[Read more…]

How NanoCellect is Revolutionizing Cell Analysis and Sorting for Stem Cells
(and Other Fragile Samples)

By 1 Comment

NanocellectNanoCellect® is a biotechnology company that facilitates breakthrough biomedical discoveries through cutting-edge cell analysis and sorting technology. Delivering sterile, portable, intuitive solutions for sorting fragile samples (such as stem cells), NanoCellect is pushing the status quo of flow cytometry to empower biomedical scientists with higher viability cells, minimal risk of sample-to-sample contamination, and efficient workflows. [Read more…]

How Celularity is Leading the Next Evolution in Cellular Medicine

By 2 Comments

Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT™ platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases.

Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]

BioInformant's World-Class Clients